[go: up one dir, main page]

DZ2200A1 - Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase. - Google Patents

Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase.

Info

Publication number
DZ2200A1
DZ2200A1 DZ970087A DZ970087A DZ2200A1 DZ 2200 A1 DZ2200 A1 DZ 2200A1 DZ 970087 A DZ970087 A DZ 970087A DZ 970087 A DZ970087 A DZ 970087A DZ 2200 A1 DZ2200 A1 DZ 2200A1
Authority
DZ
Algeria
Prior art keywords
cyclooxygenase
compositions
once daily
diseases mediated
daily treatment
Prior art date
Application number
DZ970087A
Other languages
English (en)
Inventor
Barry Gertz
Bruno Hancock
Ellot Ehrich
Conrad Winters
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DZ2200A1 publication Critical patent/DZ2200A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
DZ970087A 1996-05-17 1997-05-14 Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase. DZ2200A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (1)

Publication Number Publication Date
DZ2200A1 true DZ2200A1 (fr) 2004-06-20

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970087A DZ2200A1 (fr) 1996-05-17 1997-05-14 Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase.

Country Status (28)

Country Link
US (1) US6063811A (fr)
EP (1) EP0910368A1 (fr)
JP (1) JPH11512754A (fr)
KR (1) KR100373622B1 (fr)
CN (1) CN1140267C (fr)
AR (1) AR012014A1 (fr)
AU (1) AU3004997A (fr)
BG (1) BG103000A (fr)
BR (1) BR9709097A (fr)
CA (1) CA2254061C (fr)
CO (1) CO5050370A1 (fr)
CZ (1) CZ291463B6 (fr)
DZ (1) DZ2200A1 (fr)
EA (1) EA001596B1 (fr)
EE (1) EE03746B1 (fr)
HR (1) HRP970262A2 (fr)
HU (1) HUP9902889A3 (fr)
ID (1) ID16921A (fr)
IL (1) IL126899A (fr)
IS (1) IS4891A (fr)
MY (1) MY116201A (fr)
NO (1) NO985342D0 (fr)
NZ (1) NZ332670A (fr)
PE (1) PE66998A1 (fr)
PL (1) PL188649B1 (fr)
SK (1) SK284330B6 (fr)
TR (1) TR199802345T2 (fr)
WO (1) WO1997044028A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
WO1999045913A1 (fr) * 1998-03-13 1999-09-16 Merck & Co., Inc. Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
AU2731401A (en) * 1999-12-22 2001-07-03 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
EA011309B1 (ru) 2000-06-13 2009-02-27 Вайет Составы для ослабления боли, содержащие целекоксиб
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
AU2001285011A1 (en) * 2000-08-18 2002-03-04 Pharmacia Corporation Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AU2002303577B2 (en) * 2001-05-04 2006-06-08 Merck & Co., Inc. Method and compositions for treating migraines
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
EP1490035A1 (fr) * 2001-09-26 2004-12-29 Pharmacia Corporation Compositions de valdecoxib se d sint grant dans la bouche
NZ532184A (en) * 2001-10-10 2005-12-23 Pharmacia Corp Intraorally disintegrating valdecoxib compositions in which the excipient - a saccharide - is present in intimate association in an amount between 50% and 90%
NZ534587A (en) * 2002-03-07 2007-08-31 Novartis Ag Pharmaceutical composition containing 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid to treat a cyclooxygenase-2 dependent disorder
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
EP1534305B9 (fr) 2003-05-07 2007-03-07 Osteologix A/S Sels de strontium hydrosolubles pour le traitement d'affections de cartilage et/ou d'os
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
WO2020210341A1 (fr) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Traitement de fièvres hémorragiques virales avec des médicaments anti-inflammatoires non stéroïdiens sélectifs de cox-2
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0739340A1 (fr) * 1994-01-10 1996-10-30 Merck Frosst Canada Inc. Heterocycles phenyliques utilises comme inhibiteurs de cox-2

Also Published As

Publication number Publication date
CZ373898A3 (cs) 1999-06-16
MY116201A (en) 2003-11-28
SK156798A3 (en) 2000-01-18
BR9709097A (pt) 1999-08-03
AR012014A1 (es) 2000-09-27
KR20000011082A (ko) 2000-02-25
IL126899A0 (en) 1999-09-22
EE03746B1 (et) 2002-06-17
IS4891A (is) 1998-11-10
CO5050370A1 (es) 2001-06-27
AU3004997A (en) 1997-12-09
CA2254061C (fr) 2003-12-02
CN1140267C (zh) 2004-03-03
PL329940A1 (en) 1999-04-26
EE9800393A (et) 1999-06-15
JPH11512754A (ja) 1999-11-02
PL188649B1 (pl) 2005-03-31
CA2254061A1 (fr) 1997-11-27
EA001596B1 (ru) 2001-06-25
ID16921A (id) 1997-11-20
CZ291463B6 (cs) 2003-03-12
EP0910368A1 (fr) 1999-04-28
US6063811A (en) 2000-05-16
BG103000A (en) 1999-09-30
NO985342L (no) 1998-11-16
TR199802345T2 (xx) 1999-03-22
CN1225010A (zh) 1999-08-04
HUP9902889A2 (hu) 2002-01-28
EA199801017A1 (ru) 1999-04-29
NZ332670A (en) 2000-07-28
NO985342D0 (no) 1998-11-16
IL126899A (en) 2004-03-28
WO1997044028A1 (fr) 1997-11-27
HK1021623A1 (en) 2000-06-23
PE66998A1 (es) 1998-10-24
KR100373622B1 (ko) 2003-07-12
HRP970262A2 (en) 1998-06-30
SK284330B6 (sk) 2005-01-03
HUP9902889A3 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
DZ2200A1 (fr) Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase.
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
FR15C0070I2 (fr) Composes heteroaromatiques azotes pour le traitement des maladies de cancer
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
DZ3500A1 (fr) Derives de phenethanolamine pour le traitement de maladies respiratoires
MA28289A1 (fr) Immunoglobulines
MA25823A1 (fr) Compositions pour le traitement de l'eau.
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
EP1438062A4 (fr) Methodes et compositions pour le traitement de lesions cutanees
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
EP0946178A4 (fr) Traitement combine destine a reduire les risques de maladies cardio-vasculaires
DE69519577D1 (de) Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes
EP0959879A4 (fr) Therapie photodynamique pour le traitement de l'arthrose
EP1126850A4 (fr) Traitement des affections de la retine
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
EP0770394A3 (fr) Composition contenant des extraits de plantes pour le traitement de la mastite bovine
TNSN02038A1 (fr) Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
MA25852A1 (fr) Methode pour le traitement de l'inflammation.